

### AMENDMENTS TO THE CLAIMS

Please amend this application as described in the Listing of Claims, which will replace all prior versions and listings of claims in the above-referenced application.

### LISTING OF CLAIMS

1. (Currently amended) A pharmaceutical ~~composition-product~~ device comprising:
  - a. an aqueous solution formulation of a Y2 receptor binding ~~compound~~ peptide at a concentration sufficient to produce therapeutically effective plasma concentrations and L- $\alpha$ -phosphatidylcholine didecanoyl (DDPC); and
  - b. an actuator able to produce an aerosol of said solution, wherein the spray pattern ellipticity ratio of said aerosol is between 1.00 and 1.40 when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
- 2-3. (Canceled)
4. (Currently amended) The ~~product device~~ of claim 1, wherein said actuator produces an ellipticity of between 1.00 and 1.30.
5. (Currently amended) The ~~product device~~ of claim 1, comprising an aerosol of between 20 and 200 microliters per actuation.
6. (Currently amended) The ~~product device~~ of [[claim 3]] claim 1, wherein said ellipticity is between 1.15 and 1.25.
7. (Currently amended) A pharmaceutical ~~composition-product~~ device comprising:
  - a. an aqueous solution of a Y2 receptor binding ~~compound~~ peptide, and L- $\alpha$ -phosphatidylcholine didecanoyl (DDPC); and
  - b. an actuator to produce an aerosol of said solution, wherein the spray pattern major and minor axes of said aerosol are between 10 and 50 mm when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
- 8-9. (Canceled)

10. (Currently amended) The ~~product~~ device of claim 7 comprising an aerosol of between 20 and 200 microliters per actuation.
11. (Currently amended) A pharmaceutical ~~composition~~ product device comprising:
- a. an aqueous solution formulation of a Y2 receptor binding ~~compound~~ peptide at a concentration sufficient to produce therapeutically effective plasma effective plasma concentrations and L- $\alpha$ -phosphatidylcholine didecanoyl (DDPC); and
  - b. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.
12. (Currently amended) The ~~product~~ device of claim 11, wherein less than 5% of the droplets are smaller than 10 microns in size.
13. (Currently amended) The ~~product~~ device of claim 11, wherein less than 1% of the droplets are smaller than 10 microns in size.
14. (Currently amended) The ~~product~~ device of claim 11, comprising an aerosol of between 20 and 200 microliters per actuation.
15. (Currently amended) A pharmaceutical ~~composition~~ product device comprising:
- a. an aqueous solution formulation of a Y2 receptor binding ~~compound~~ peptide at a concentration sufficient to produce therapeutically effective plasma concentrations effective plasma concentrations and L- $\alpha$ -phosphatidylcholine didecanoyl (DDPC); and
  - b. an actuator selected to produce an aerosol of said solution, wherein droplets between 25 and 700 microns are produced.
16. (Currently amended) The ~~product~~ device of claim 15, comprising an aerosol of between 20 and 200 microliters per actuation.
17. (Currently amended) The ~~product~~ device of claim 1, wherein the Y2 receptor binding ~~compound~~ peptide comprises PYY(3-36).
18. (Currently amended) The ~~product~~ device of claim 17, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200  $\mu$ g/mL.

19. (Currently amended) The ~~product~~ device of claim 7, wherein the Y2 receptor binding ~~compound~~ peptide comprises PYY(3-36).

20. (Currently amended) The ~~product~~ device of claim 19, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200 µg/mL.

21. (New) The device of claim 17, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

22. (New) The device of claim 19, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

23. (New) The device of claim 11, wherein the Y2 receptor binding peptide comprises PYY(3-36).

24. (New) The device of claim 23, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

25. (New) The device of claim 23, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200 µg/mL.

26. (New) The device of claim 17, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200 µg/mL.

27. (New) The device of claim 1, wherein the composition is further comprised of at least two polyols.

28. (New) The device of claim 27, wherein the polyols are selected from the group consisting of sucrose, mannitol, sorbitol, lactose, L-arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, trehalose, D-galactose, lactulose, cellobiose, gentibiose, glycerin and polyethylene glycol.

29. (New) The device of claim 28, wherein the polyols are lactose and sorbitol.

30. (New) The device of claim 1, further comprising ethylene diamine tetraacetic acid (EDTA) or ethylene glycol tetraacetic acid (EGTA).

31. (New) The device of claim 30, comprising EDTA.

32. (New) The device of claim 1, further comprising a solubilizing agent selected from the group consisting of a cyclodextran, hydroxypropyl- $\beta$ - cyclodextran, sulfobutylether- $\beta$ -cyclodextran and methyl- $\beta$ -cyclodextrin.

33. (New) The device of claim 32, wherein the solubilizing agent is a methyl- $\beta$ -cyclodextrin.

34. (New) The device of claim 1, wherein the aqueous PYY composition has a pH of about of about 3 to about 6.

35. (New) The device of claim 34, wherein the pH of the aqueous PYY composition is  $5.0 \pm 0.3$ .

36. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. methyl- $\beta$ -cyclodextrin, EDTA, lactose, sorbitol, and L- $\alpha$ -phosphatidylcholine didecanoyl, and
- c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

37. (New) The device of claim 36, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

38. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. sodium citrate, citric acid, methyl- $\beta$ -cyclodextrin, EDTA, lactose, sorbitol, and L- $\alpha$ -phosphatidylcholine didecanoyl, wherein the formulation has a pH of about  $5.0 \pm 0.3$ , and

c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

39. (New) The device of claim 38, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

40. (New) The device of claim 38, further comprising a preservative selected from the group consisting of chlorobutanol and benzalkonium chloride.

41. (New) The device of claim 40, wherein the preservative is chlorobutanol.

42. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. chlorobutanol, sodium citrate, citric acid, methyl- $\beta$ -cyclodextrin, EDTA, lactose, sorbitol, and L- $\alpha$ -phosphatidylcholine didecanoyl, wherein the formulation has a pH of about  $5.0 \pm 0.3$ , and

c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

43. (New) The device of claim 42, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

44. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. benzalkonium chloride, sodium citrate, citric acid, methyl- $\beta$ -cyclodextrin, EDTA, lactose, sorbitol, and L- $\alpha$ -phosphatidylcholine didecanoyl, wherein the formulation has a pH of about  $5.0 \pm 0.3$ , and

c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

45. (New) The device of claim 44, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

46. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. chlorobutanol at a concentration of 5mg/ml, sodium citrate at a concentration of 1.62 mg/ml, citric acid at a concentration of 0.86 mg/ml, methyl- $\beta$ -cyclodextrin at a concentration of 45 mg/ml, EDTA at a concentration of 1 mg/ml, lactose at a concentration of 9 mg/ml, sorbitol at a concentration of 18.2 mg/ml, and L- $\alpha$ -phosphatidylcholine didecanoyl at a concentration of 1 mg/ml, wherein the formulation has a pH of about  $5.0 \pm 0.3$ , and
- c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

47. (New) The device of claim 46, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).

48. (New) A pharmaceutical device comprising:

- a. an aqueous solution formulation of a Y2 receptor binding peptide at a concentration sufficient to produce therapeutically effective plasma concentrations,
- b. chlorobutanol at a concentration of 5mg/ml, sodium citrate at a concentration of 1.62 mg/ml, citric acid at a concentration of 0.86 mg/ml, methyl- $\beta$ -cyclodextrin at a concentration of 45 mg/ml, EDTA at a concentration of 1 mg/ml, lactose at a concentration of 9 mg/ml, sorbitol at a concentration of 18.2 mg/ml, and L- $\alpha$ -phosphatidylcholine didecanoyl at a concentration of 1 mg/ml, wherein the formulation has a pH of about  $5.0 \pm 0.3$ , and
- c. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.

49. (New) The device of claim 48, wherein the Y2 receptor binding peptide comprises PYY(3-36) (SEQ ID NO:2).